EnGeneIC Ltd. to Present at The 14th Annual BIO Investor Forum

NEW YORK and SYDNEY, Oct. 15, 2015 /PRNewswire/ -- EnGeneIC Ltd., a clinical stage biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced it will present at The 14th Annual BIO Investor Forum to be held October 20-21, 2015 at the Parc 55 San Francisco.

Himanshu Brahmbhatt, Ph.D., joint-CEO and director of EnGeneIC, will provide an overview of the company's business, groundbreaking EDV™ nanocell technology platform, and rapidly advancing development pipeline during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

About EDV™ Nanocell Technology
EnGeneIC's bacterially-derived EDV™ nanocells are a powerful nanoparticle drug, siRNA, or miRNA delivery system designed to directly target and effectively kill tumor cells with minimal toxicity, while at the same time stimulate the immune system's natural anti-tumor response. Intravenously injected EDV™ nanocells exit the leaky vascular system only within tumors and attach to cancer cells via a specially designed, targeted bi-specific antibody. Once attached, the nanocell is able to enter the tumor cell and deliver intracellularly a drug, siRNA, or miRNA payload. In parallel, the bacterial cell wall of the nanocells stimulates key components of the immune system, which are then activated to seek out and destroy cancer cells.

About EnGeneIC
EnGeneIC is an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutic and other therapeutic molecules.  The company's lead technology platform, EDV™ utilizes antibody-targeted, bacterially derived, non-living "nanocells" to release high concentrations of chemotherapeutic agents, molecularly targeted drugs, and RNA-interference molecules directly into targeted tumor cells.  In doing so, EDVTM nanocells enable current cancer treatments to be more potent and far less toxic, while also offering a potential new means for treating drug-resistant cancers.  EnGeneIC is currently planning to undertake clinical trials in several cancer indications in Australia and USA.

For more information, please visit www.engeneic.com.

***

For EnGeneIC:
Himanshu Brahmbhatt, Ph.D.
Joint-CEO and Director
+61-438-020-856
[email protected]

U.S. Investor Contact:
Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D. 
+1-212-375-2664
[email protected]  

U.S. Media Contact:
Tiberend Strategic Advisors, Inc. 
Amy S Wheeler
+1-646-362-5750
[email protected] 

Australia Media Contact:
Felicity Moffatt
+61-418-677701
[email protected] 

SOURCE EnGeneIC Ltd.

Related Links

http://www.engeneic.com